Healthcare
Natco Pharma Limited (NSE: Natcopharm) Completes Acquisition of Additional 13.25% Stake in Adcock Ingram
Natco Pharma Limited (NSE: NATCOPHARM) announced the completion of acquiring an additional 13.25% stake in Adcock Ingram, boosting its ownership to 49%.
Natco Pharma Limited (NSE: NATCOPHARM) announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited (Adcock Ingram), a leading South African pharmaceutical and healthcare company. With this transaction, NATCO’s shareholding in Adcock Ingram has increased from 35.75% to 49%.
Strategic Milestone
This acquisition marks a significant milestone in NATCO’s long-term Africa strategy. The company first acquired 35.75% in Adcock Ingram in 2025 following a delisting process. The board then approved the acquisition of an additional 13.25% stake in July 2026, which has now been completed.
Transaction Details
The transaction involved acquiring shares for an aggregate consideration of around ZAR 1.81 billion, equivalent to approximately ₹ 1,060 crores at the transaction exchange rate. The acquisition was executed through NATCO Pharma South Africa Proprietary Limited, NATCO’s wholly owned subsidiary in South Africa.
Natco Pharma Limited is a public limited company listed on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalization of ~US$ 1.82 billion. Established in 1981, NATCO Pharma is recognized for its innovation in pharmaceutical R&D and its focus on developing niche, high-potential molecules.
As a result, NATCO Pharma continues to expand its footprint in Africa, strengthening its position in the pharmaceutical market.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Natco Pharma Limited
Natco Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Natco falls 9.0% over three months and has not found a floor yet. The PEG of 0.48 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Industry-leading margins of 34.8% reflect exceptional pricing power and operational efficiency. The stock gains 13.4% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 14.8% and profits at 25.6% CAGR, with D/E of 0.04. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Natco Pharma Limited.
Healthcare
Zydus Lifesciences Limited (zyduslife) USFDA Inspection Concludes at Moraiya Plant with 5 Observations
Zydus Lifesciences Limited (ZYDUSLIFE) announces the conclusion of USFDA inspection at its Moraiya plant, with 5 observations noted.
Zydus Lifesciences Limited (ZYDUSLIFE) announced the conclusion of a USFDA inspection at its manufacturing plant located in Moraiya, Ahmedabad. The inspection, conducted from October 5th to October 13th, 2026, concluded with five observations noted by the USFDA. The company will closely collaborate with the USFDA to address these observations promptly. This announcement is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Inspection Details
The USFDA conducted a thorough inspection of the company’s manufacturing facility. The primary objective was to ensure compliance with Good Manufacturing Practices (GMP) and other regulatory requirements. The inspection team identified five observations that need to be addressed by the company.
Company’s Response
Zydus Lifesciences Limited has assured that it will work closely with the USFDA to resolve the observations expeditiously. The company’s management emphasized their commitment to maintaining high standards of quality and compliance in all its operations. The observations will be addressed in a timely manner to ensure continued adherence to regulatory requirements.
Forward-Looking Statement
As a result of this inspection, Zydus Lifesciences Limited remains dedicated to improving its manufacturing processes and ensuring the highest quality standards for its products. The company looks forward to maintaining a strong relationship with the USFDA and other regulatory bodies.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Zydus Lifesciences Limited
Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.69 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock gains 1.2% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.
Healthcare
Zydus Lifesciences Limited (zyduslife) Announces USFDA Acceptance of Fyb206 Biosimilar
Zydus Lifesciences Limited (ZYDUSLIFE) announces USFDA acceptance of FYB206, a biosimilar to Keytruda®.
Zydus Lifesciences Limited (ZYDUSLIFE) has announced that the US Food and Drug Administration (USFDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda®. This marks the first publicly announced acceptance by the USFDA of an application for a Keytruda® biosimilar. The BLA was submitted in the third quarter of 2026.
Significant Milestone
The acceptance of the application is a significant step toward expanding access to affordable pembrolizumab therapy in the U.S. and Canada. The regulatory dossier for FYB206 has also been submitted to Health Canada. This development is expected to improve patient access and outcomes in oncology treatment.
Development Pathway
FYB206 was developed without a comparative Phase III efficacy trial, following a development pathway agreed upon with the USFDA in early 2025. Zydus holds exclusive commercialization rights for the United States and Canada and brings extensive commercial experience in the North American market for this product.
Future Outlook
Under the Biosimilar User Fee Amendments (BsUFA), the USFDA aims to complete its review within twelve months of submission. A decision could be expected in the third quarter of 2027. With this milestone, Zydus and Formycon aim to make this important cancer therapy accessible to more patients.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Zydus Lifesciences Limited
Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 75% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.
Healthcare
Max India Limited (maxind) Launches SCALE with Antara Senior Care to Advance Senior-care Research
Max India Foundation and ISB launch SCALE with Antara Senior Care to advance senior-care research, focusing on scalable solutions for India’s growing senior.
Max India Limited (MAXIND) has launched the SCALE initiative in collaboration with the Max Institute of Healthcare Management (MIHM) at the Indian School of Business (ISB) and Antara Senior Care to advance senior-care research. The SCALE initiative aims to bridge research and industry experience to develop scalable solutions for India’s rapidly growing senior population.
Addressing the Gap in Senior-Care Research
India is witnessing an increasing demand for senior care that is accessible, appropriate, and sustainable. However, these learnings remain fragmented. The SCALE Initiative seeks to address this gap by generating evidence and translating it into insights that can assist industry stakeholders and policymakers to make informed decisions.
Focus Areas of the SCALE Initiative
The initiative will focus on consumer behavior, workforce participation, social inclusion, operating and care delivery models, and technology adoption. Antara Senior Care, as the founding industry partner, is supporting SCALE’s engagement with the senior care sector.
Future of Senior Care in India
SCALE will bring together researchers, senior care industry stakeholders, and clinicians to examine the evolving care needs of seniors and identify priority action areas. The initiative aims to build an industry-level evidence base to help organizations innovate, respond to evolving consumer needs, make informed business and investment decisions, strengthen workforce strategies, and scale effective approaches.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Max India Limited
Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.
Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 6.6% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.
-
HCLTECH2 days agoHcl Technologies Limited (hcltech) Q2 FY27: Revenue ₹35,620cr ↑3.0% Qoq ↑11.5% Yoy
-
Consumer Cyclical2 days agoCrompton Greaves Consumer Electricals Limited Launches Instanourish Pro Multi Purpose Kettle
-
Basic Materials2 days agoGoodluck India Limited (goodluck) Recognized as Sole Qualified Bidder for Defence Artillery Shells
-
Banks - Regional2 days agoRbl Bank Limited (rblbank) Q2 FY27: Net Profit Surges 170% Yoy
-
Industrials2 days agoSkipper Limited (skipper) Appoints Mr. R. N. Nayak as Non-executive Independent Director
-
AEQUS2 days agoAequs Limited (aequs) Announces Long-term Supply Agreements with Safran for Aerospace Applications
-
Banks - Regional2 days agoThe Karnataka Bank Limited Launches Trade Konnect Digital Platform
-
Healthcare2 days agoZydus Lifesciences Limited (zyduslife) Shares New Post Hoc Analysis of Phase 3 Epics-iii Trial Showing Greater Biochemical Response with Investigational Saroglitazar